GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...
British drugmaker GSK said on Wednesday it had agreed to settle two lawsuits in California that claimed its discontinued ...
British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot ...
The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...
Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...
J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of ...
If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...
GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older.
GlaxoSmithKline (GSK) has firmly acquired the number one position in the Egyptian pharmaceutical market since 2009 and is likely to maintain the grip at least until the end of 2011. GSK’s ...
GSK signs AllTrials data transparency campaign In an unusual development, one day after the Pharmaceutical Research &, Manufacturers of America trade group in the US harshly criticized a call ...
Meanwhile, GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK), a global biopharma company, recently launched a new vaccine called Shingrix to prevent shingles. Shingrix is also known as Recombinant Zoster ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback